Clearside Biomedical Inc.

09/21/2021 | Press release | Distributed by Public on 09/21/2021 05:09

Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients